	US 11,725,244 B2
	Genetic markers for engraftment of human cardiac ventricular progenitor cells
Chuen Yan Leung, Stockholm (SE); Jonathan Clarke, Stockholm (SE); Jiejia Xu, Solna (SE); Federica Santoro, Stockholm (SE); Makoto Sahara, Stockholm (SE); and Kenneth R. Chien, Cambridge, MA (US)
Assigned to Procella Therapeutics AB, Tullinge (SE)
Filed by Procella Therapeutics AB, Tullinge (SE)
Filed on Mar. 3, 2020, as Appl. No. 16/807,943.
Application 16/807,943 is a continuation of application No. 15/433,713, filed on Feb. 15, 2017, granted, now 10,612,094.
Claims priority of provisional application 62/297,217, filed on Feb. 19, 2016.
Prior Publication US 2020/0270685 A1, Aug. 27, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6881 (2018.01); A61K 35/34 (2015.01); C12N 5/077 (2010.01)

CPC C12Q 1/6881 (2013.01) [A61K 35/34 (2013.01); C12N 5/0657 (2013.01); C12N 2501/415 (2013.01); C12N 2501/42 (2013.01); C12Q 2600/158 (2013.01)]

21 Claims

1. A method of identifying engraftable human ventricular progenitor cells (HVPs), the method comprising:

subjecting human pluripotent stem cells to activation of Wnt/β-catenin signaling on day 0 of culture, followed by inhibition of Wnt/β-catenin signaling from day 3 to day 5 of culture to thereby obtain a culture of cardiac progenitor cells (CPCs) comprising LIFR+Islet 1+human ventricular progenitor cells (HVPs);

isolating the LIFR+Islet 1+HVPs on day 5, day 6 or day 7 of culture; and

detecting expression of at least one engraftment marker on the LIFR+Islet 1+HVPs to thereby detect the engraftable HVPs.